The US FTC approves a final order settling charges that a merger between two pharmaceutical companies harmed competition in the markets for an antibiotic used to treat infections and an oral steroid product used to treat inflammation (ANI Pharmaceuticals / Novitium Pharma)
FTC Approves Final Order Requiring Generic Drug Marketers ANI Pharmaceuticals, Inc. and Novitium Pharma LLC to Divest Rights and Assets to Generic Sulfamethoxazole-Trimethoprim Oral
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.